Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: StockDung who wrote (14878)	3/30/2005 7:02:15 PM
From: SEC-ond-chance	Respond to of 19428

==================================================================================== === VisualRoute (R) 2005 Server Edition (v9.1a) Mar 30, 2005 ===================================================================================== Report for primepennystock.com [69.20.106.69] Analysis: 'primepennystock.com' was found in 12 hops (TTL=118). ------------------------------------------------------------------------------------------------------------------------------------------------------------------- \| Hop \| %Loss \| IP Address \| Node Name \| Location \| Tzone \| ms \| Graph \| Network \| ------------------------------------------------------------------------------------------------------------------------------------------------------------------- \| 0 \| \| 161.58.180.113 \| WIN10115.visualware.com \| * \| \| \| \| Verio, Inc. VRIO-161-058 \| \| 1 \| \| 161.58.176.129 \| - \| ?Englewood, CO \| \| 0 \| \| Verio, Inc. VRIO-161-058 \| \| 2 \| \| 161.58.156.140 \| - \| ?Englewood, CO \| \| 0 \| \| Verio, Inc. VRIO-161-058 \| \| 3 \| \| 129.250.28.206 \| xe-1-2-0-3.r20.asbnva01.us.bb.verio.net \| Ashburn, VA, USA \| -05:00 \| 0 \| \| Verio, Inc. VRIO-129-250 \| \| 4 \| \| 129.250.9.70 \| p16-0.uunet.asbnva01.us.bb.verio.net \| Ashburn, VA, USA \| -05:00 \| 0 \| \| Verio, Inc. VRIO-129-250 \| \| 5 \| \| 152.63.43.170 \| 0.so-5-0-0.XL1.DCA5.ALTER.NET \| Washington, DC, USA \| -05:00 \| 0 \| \| UUNET Technologies, Inc. UUNET-BACKBONE \| \| 6 \| \| 152.63.42.190 \| 0.so-7-0-0.XL1.DCA6.ALTER.NET \| Washington, DC, USA \| -05:00 \| 0 \| \| UUNET Technologies, Inc. UUNET-BACKBONE \| \| 7 \| \| 152.63.41.221 \| 0.so-6-0-0.GW6.DCA6.ALTER.NET \| Washington, DC, USA \| -05:00 \| 0 \| \| UUNET Technologies, Inc. UUNET-BACKBONE \| \| 8 \| \| 157.130.73.202 \| rackspace-gw.customer.alter.net \| ?Ashburn, VA, USA \| -05:00 \| 0 \| \| UUNET Technologies, Inc. UUNETCUSTB40 \| \| 9 \| \| 69.20.1.40 \| vlan903.core3.iad1.rackspace.com \| ?San Antonio, TX \| \| 0 \| \| Rackspace.com RSPC-NET-4 \| \| 10 \| \| 69.20.3.35 \| aggr108a.iad1.rackspace.com \| ?San Antonio, TX \| \| 0 \| \| Rackspace.com RSPC-NET-4 \| \| 11 \| \| 69.20.106.69 \| - \| ?Woodland Hills, CA \| \| 0 \| \| Clicks2Customers Inc RSPC-49291-1094693438 \| \| 12 \| \| 69.20.106.69 \| primepennystock.com \| ?Woodland Hills, CA \| \| 0 \| \| Clicks2Customers Inc RSPC-49291-1094693438 \| -------------------------------------------------------------------------------------------------------------------------------------------------------------------

To: StockDung who wrote (14878)	3/30/2005 7:16:00 PM
From: SEC-ond-chance	Respond to of 19428

Sounds like HeySEC RECOMMENDATION TO INDIVIDUAL INVESTORS For Individual Investors seeking significant near-term capital appreciation google.com on a modest investment position in an emerging growth company, a $2,000 to $10,000 investment in BIO-heal will buy up to 3300 shares of stock at current prices. Given a minimum target price of $32 per share, this represents an extraordinary profit opportunity. Even the $32 per share minimum target price expected by year's end translates into a $29 per share capital gain --- or a potential gain of $95,700 on an initial $10,000 investment. For more aggressive Individual Investors, consider a $20,000 investment position, to purchase up to 6800 shares. Based on an Exit Strategy of $32 -- this position represents potential gains in excess of $190,000

To: StockDung who wrote (14878)	3/30/2005 8:56:22 PM
From: SEC-ond-chance	Read Replies (2) \| Respond to of 19428

Now I've seen it all! biolabamerica.com

To: StockDung who wrote (14878)	3/31/2005 5:37:16 AM
From: RockyBalboa	Read Replies (1) \| Respond to of 19428

findarticles.com Business Editors and Health/Medical Writers BERMUDA DUNES, Calif.--(BW HealthWire)--Jan. 31, 2002 Nutra Pharma Corp. (OTCBB:NPHC) announced today that it has signed a joint venture agreement to develop a new bio pharmaceutical product with Terra BioPharma, the developer of an organic medicinal compound used in wound healing. The company announced that it will invest the sum of $1.8 million in the development of the drug, including further clinical trials and several patent applications. "The first two patents for the drug will be for the treatment of diabetic sores and psoriasis," said CEO Dr. Michael Flax. Under the joint venture agreement, Nutra Pharma Corp. advances its relationship with Terra BioPharma from an exclusive distributor to co-owner of the products. On Nov. 23, 2001, Nutra Pharma Corp. acquired 100% of Nutra Pharma Inc., a Nevada corporation which held the exclusive worldwide distribution rights for all products to be developed from the compound. The joint venture agreement announced today involves the formation of a joint venture subsidiary, which will be owned 50% by Nutra Pharma Corp. and 50% by Terra BioPharma. This subsidiary will own all of the use patents for all of the products to be developed. "Terra BioPharma is excited to be a part of this joint venture, and we are in the process of setting up our clinic in Managua to complete clinical trials on the product," said Dr. Ennio Devoto, CEO of Terra BioPharma. This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Nutra Pharma Corp. and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results. For further information, contact Investor Relations at 866/295-3162. COPYRIGHT 2002 Business Wire COPYRIGHT 2002 Gale Group

To: StockDung who wrote (14878)	3/31/2005 6:07:39 AM
From: RockyBalboa	Respond to of 19428

Steven Georgiev has been: Chief Executive Officer of Palomar Medical Technologies, Inc. (a publicly traded company); Director of Nexar Technologies Inc. (a publicly traded company); Director of Excel Technology, Inc. (a publicly traded company). Mr. Georgiev earned a B.S. degree in Engineering Physics from Cornell University and a M.S. in Management from the Massachusetts Institute of Technology. Mr. Georgiev became a Director of Dynagen in July 1996. In November 1993, he became Chief Executive Officer of Palomar Medical Technologies, Inc., a publicly traded Massachusetts firm specializing in medical applications of lasers. Mr. Georgiev was a consultant to Palomar's predecessor, Dymed Corporation, from June 1991 until Palomar's September 1991 merger with Dymed Corporation, at which time he became Chairman of the Board of Directors. Mr. Georgiev has been a director of Excel Technology, Inc., a publicly traded laser system and electro-optical component company, beginning in October 1992, and of XXSYS Technology, Inc. beginning in June 1994. Mr. Georgiev was a Director of Senetek PLC from February 1997 until May 14, 2002.